Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT03271632, who can take part
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT03271632
- Record updated
- 30 October 2026
- Original description
The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.Read full original descriptionShow less
Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma
The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
Inclusion: Male and female subjects with surface antigen confirmed multiple myeloma with no available curative treatment options (including autologous or allogeneic SCT); Complete remission (CR) cannot be achieved after at least 4 prior combination therapy regimens; MM in CR2 or CR3 and not eligible for allogeneic SCT because of age, comorbid diseases, or lack of available donor; Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval < 1 year); Relapsed after prior autologous or allogenic SCT MM patients with relapsed or residual disease after at least 1 prior therapy and not eligible for allogeneic SCT; Residual disease after primary therapy and not eligible for ASCT; Expected survival > 12 weeks; Creatinine < 2.5 mg/dl; ALT (alanine aminotransferase)/AST (aspartate aminotransferase) < 3x normal; Bilirubin < 2.0 mg/dl; Any relapse after prior SCT is eligible regardless of other prior therapy; Adequate venous access for apheresis, and no other contraindications for leukapheresis; Voluntary informed consent is given.
Exclusion: Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary; Previous related CAR-T cell therapy Any uncontrolled active medical disorder that would preclude participation; Uncontrolled active infection; Active hepatitis B or hepatitis C infection; HIV infection; Pregnant or lactating women.